Qinchao Wu1, Baochen Bai1, Chao Tian1, Daisong Li1, Haichu Yu1, Bingxue Song1, Bing Li2,3, Xianming Chu4,5. 1. Department of Cardiology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, 266100, Shandong, China. 2. Department of Hematology, The Affiliated Hospital of Qingdao University, No.16 Jiangsu Road, Qingdao, Shandong, China. libing_516619@163.com. 3. Department of Genetics and Cell Biology, Basic Medical College, Qingdao University, No. 308 Ningxia Road, Qingdao, 266000, Shandong, China. libing_516619@163.com. 4. Department of Cardiology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao, 266100, Shandong, China. 18661801698@163.com. 5. The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao, Shandong, China. 18661801698@163.com.
Abstract
AIM: In recent decades, there has been a revolutionary decrease in cancer-related mortality and an increase in survival due to the introduction of novel targeted drugs. Nevertheless, drugs targeting human epidermal growth factor receptor 2 (HER-2), angiogenesis, and other tyrosine kinases also come with unexpected cardiac side effects, including heart failure, hypertension, arterial thrombosis, and arrhythmias, and have mechanisms that are unlike those of classic chemotherapeutic agents. In addition, it is challenging to address some problems, as the existing guidelines need to be more specific, and further large-scale clinical trials and experimental studies are required to confirm the benefit of administering cardioprotective agents to patients treated with targeted therapies. Therefore, an improved understanding of cardiotoxicity becomes increasingly important to minimize the pernicious effects and maximize the beneficial effects of targeted agents. METHODS: "Cardiotoxicity", "targeted drugs", "HER2", "trastuzumab", "angiogenesis inhibitor", "VEGF inhibitor" and "tyrosine kinase inhibitors" are used as keywords for article searches. RESULTS: In this article, we report several targeted therapies that induce cardiotoxicity and update knowledge of the clinical evidence, molecular mechanisms, and management measures.
AIM: In recent decades, there has been a revolutionary decrease in cancer-related mortality and an increase in survival due to the introduction of novel targeted drugs. Nevertheless, drugs targeting human epidermal growth factor receptor 2 (HER-2), angiogenesis, and other tyrosine kinases also come with unexpected cardiac side effects, including heart failure, hypertension, arterial thrombosis, and arrhythmias, and have mechanisms that are unlike those of classic chemotherapeutic agents. In addition, it is challenging to address some problems, as the existing guidelines need to be more specific, and further large-scale clinical trials and experimental studies are required to confirm the benefit of administering cardioprotective agents to patients treated with targeted therapies. Therefore, an improved understanding of cardiotoxicity becomes increasingly important to minimize the pernicious effects and maximize the beneficial effects of targeted agents. METHODS: "Cardiotoxicity", "targeted drugs", "HER2", "trastuzumab", "angiogenesis inhibitor", "VEGF inhibitor" and "tyrosine kinase inhibitors" are used as keywords for article searches. RESULTS: In this article, we report several targeted therapies that induce cardiotoxicity and update knowledge of the clinical evidence, molecular mechanisms, and management measures.
Authors: Elizabeth Tan-Chiu; Greg Yothers; Edward Romond; Charles E Geyer; Michael Ewer; Deborah Keefe; Richard P Shannon; Sandra M Swain; Ann Brown; Louis Fehrenbacher; Victor G Vogel; Thomas E Seay; Priya Rastogi; Eleftherios P Mamounas; Norman Wolmark; John Bryant Journal: J Clin Oncol Date: 2005-11-01 Impact factor: 44.544
Authors: Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; Nancy E Davidson; Charles E Geyer; Silvana Martino; Eleftherios P Mamounas; Peter A Kaufman; Norman Wolmark Journal: J Clin Oncol Date: 2011-07-18 Impact factor: 44.544
Authors: Sandra M Swain; David Miles; Sung-Bae Kim; Young-Hyuck Im; Seock-Ah Im; Vladimir Semiglazov; Eva Ciruelos; Andreas Schneeweiss; Sherene Loi; Estefanía Monturus; Emma Clark; Adam Knott; Eleonora Restuccia; Mark C Benyunes; Javier Cortés Journal: Lancet Oncol Date: 2020-03-12 Impact factor: 41.316
Authors: Giuseppe Caruso; Anna Privitera; Barbara Moura Antunes; Giuseppe Lazzarino; Susan Marie Lunte; Giancarlo Aldini; Filippo Caraci Journal: Molecules Date: 2022-07-12 Impact factor: 4.927